Troponin T, troponin I and creatine kinase-MB mass after elective coronary stenting. 1996

L La Vecchia, and F Bedogni, and G Finocchi, and G Mezzena, and M Martini, and M Sartori, and A Castellani, and G Soffiati, and M Vincenzi
Division Clinicizzata di Cardiologia, Vicenza, Italy.

OBJECTIVE To assess whether and to what extent elective coronary stenting is associated with biochemical evidence of minor myocardial damage (MMD), as defined by the detection of abnormal post-procedural serum levels of one more among the following markers of ischaemic injury: creatine kinase (CK)-MB mass, troponin T (Tn-T) and troponin I (Tn-I). METHODS Nineteen elective procedure of coronary stenting were compared with a matched group of 25 conventional percutaneous transluminal coronary angioplasty (PTCA) procedures performed in our laboratory from March to June 1995. Cases with evolving or recent (< 2 weeks) myocardial infarction, chronic total occlusions and dilation of saphenous vein grafts were excluded. By definition, all of the patients had undergone uneventful deployment of a single palmaz-Schatz stent, with no chest pain and no persistent ECG changes after the procedure. Serum levels of CK-MB mass, Tn-T and Tn-I were determined at baseline and 6, 12 and 24 h after the procedure. The frequency of abnormal results was determined for each marker. Baseline and peak post-procedural levels in the two groups were compared and related to procedural variables. RESULTS Baseline values were normal in all cases. The quantitative analysis showed that post-procedural levels of each marker (including total CK) were significantly higher with respect to baseline in both groups. In the stent group, two patients had positive CK-MB mass, four positive Tn-T and seven positive Tn-I. Absolute changes in Tn-T and Tn-I were closely related to changes in CK-MB mass (r = 0.76, P < 0.0001; r = 0.90, P < 0.0001), respectively). Three of these patients developed clinically silent side-branch occlusion. All of them were positive for troponins and two were positive for CK-MB. No correlation was found between procedural variables and the results of biochemical assays. In the PTCA group, three patients were positive for Tn-I, whereas the CK-MB mass and Tn-T remained constantly normal. No side-branch occlusion was observed. The peak CK-MB mass and Tn-I were significantly higher in the stent group than they were in the PTCA group (3.04 +/- 4.1 versus 1.27 +/- 1.3 ng/ml, P = 0.046; 0.78 +/- 1.17 versus 0.28 +/- 0.3 ng/ml, P = 0.046, respectively). This difference was no longer apparent when patients with side-branch occlusion were excluded. CONCLUSIONS In our series, Tn-I measurement shows the highest ability to detect MMD, being positive in 37% of stent and 14% of PTCA cases. Elective coronary stenting associated with greater release of CK-MB mass and Tn-I than is conventional PTCA. This finding is mainly determined by cases of side branch occlusion, which account for most, but not all, periprocedural MMD in the stent group.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D003402 Creatine Kinase A transferase that catalyzes formation of PHOSPHOCREATINE from ATP + CREATINE. The reaction stores ATP energy as phosphocreatine. Three cytoplasmic ISOENZYMES have been identified in human tissues: the MM type from SKELETAL MUSCLE, the MB type from myocardial tissue and the BB type from nervous tissue as well as a mitochondrial isoenzyme. Macro-creatine kinase refers to creatine kinase complexed with other serum proteins. Creatine Phosphokinase,ADP Phosphocreatine Phosphotransferase,ATP Creatine Phosphotransferase,Macro-Creatine Kinase,Creatine Phosphotransferase, ATP,Kinase, Creatine,Macro Creatine Kinase,Phosphocreatine Phosphotransferase, ADP,Phosphokinase, Creatine,Phosphotransferase, ADP Phosphocreatine,Phosphotransferase, ATP Creatine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014336 Troponin One of the minor protein components of skeletal and cardiac muscles. It functions as the calcium-binding component in a complex with BETA-TROPOMYOSIN; ACTIN; and MYOSIN and confers calcium sensitivity to the cross-linked actin and myosin filaments. Troponin itself is a complex of three regulatory proteins (TROPONIN C; TROPONIN I; and TROPONIN T). Troponin Complex,Troponins

Related Publications

L La Vecchia, and F Bedogni, and G Finocchi, and G Mezzena, and M Martini, and M Sartori, and A Castellani, and G Soffiati, and M Vincenzi
August 1998, Chest,
L La Vecchia, and F Bedogni, and G Finocchi, and G Mezzena, and M Martini, and M Sartori, and A Castellani, and G Soffiati, and M Vincenzi
March 2000, Clinical chemistry,
L La Vecchia, and F Bedogni, and G Finocchi, and G Mezzena, and M Martini, and M Sartori, and A Castellani, and G Soffiati, and M Vincenzi
June 1999, Clinica chimica acta; international journal of clinical chemistry,
L La Vecchia, and F Bedogni, and G Finocchi, and G Mezzena, and M Martini, and M Sartori, and A Castellani, and G Soffiati, and M Vincenzi
June 1997, International journal of cardiology,
L La Vecchia, and F Bedogni, and G Finocchi, and G Mezzena, and M Martini, and M Sartori, and A Castellani, and G Soffiati, and M Vincenzi
January 2004, Chest,
L La Vecchia, and F Bedogni, and G Finocchi, and G Mezzena, and M Martini, and M Sartori, and A Castellani, and G Soffiati, and M Vincenzi
November 2012, American heart journal,
L La Vecchia, and F Bedogni, and G Finocchi, and G Mezzena, and M Martini, and M Sartori, and A Castellani, and G Soffiati, and M Vincenzi
November 1993, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies,
L La Vecchia, and F Bedogni, and G Finocchi, and G Mezzena, and M Martini, and M Sartori, and A Castellani, and G Soffiati, and M Vincenzi
August 2007, International journal of cardiology,
L La Vecchia, and F Bedogni, and G Finocchi, and G Mezzena, and M Martini, and M Sartori, and A Castellani, and G Soffiati, and M Vincenzi
December 1999, Clinical chemistry,
L La Vecchia, and F Bedogni, and G Finocchi, and G Mezzena, and M Martini, and M Sartori, and A Castellani, and G Soffiati, and M Vincenzi
June 2015, Journal of cardiovascular medicine (Hagerstown, Md.),
Copied contents to your clipboard!